Diseases, Conditions, Syndromes

Study finds no benefit to taking ivermectin for COVID-19 symptoms

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between participants taking ivermectin and participants ...


Early ivermectin does not reduce hospital admission in COVID-19

Early ivermectin treatment does not reduce the risk for hospital admission or prolonged emergency department observation visits for adults with symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, ...

Medical research

Ivermectin does not prevent progression to severe COVID-19

Ivermectin treatment during early illness does not prevent progression to severe disease for high-risk patients with mild-to-moderate COVID-19, according to a study published online Feb. 18 in JAMA Internal Medicine.

page 1 from 5


Ivermectin (22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b) is a broad-spectrum antiparasitic avermectin medicine.

It is sold under brand names Stromectol in the United States, Ivomec in Europe by Merial Animal Health, Mectizan in Canada by Merck and Ivexterm in Mexico by Valeant Pharmaceuticals International. While in development, it was assigned the code MK-933 by Merck.

This text uses material from Wikipedia, licensed under CC BY-SA